CRISPR/Cas9 Plasmid Delivery Through the CPP: PepFect14

2021 ◽  
pp. 587-593
Author(s):  
Luca Falato ◽  
Birgit Vunk ◽  
Ülo Langel
Keyword(s):  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Temitayo O. Idowu ◽  
Valerie Etzrodt ◽  
Thorben Pape ◽  
Joerg Heineke ◽  
Klaus Stahl ◽  
...  

Abstract Background Reduced endothelial Tie2 expression occurs in diverse experimental models of critical illness, and experimental Tie2 suppression is sufficient to increase spontaneous vascular permeability. Looking for a common denominator among different critical illnesses that could drive the same Tie2 suppressive (thereby leak inducing) phenotype, we identified “circulatory shock” as a shared feature and postulated a flow-dependency of Tie2 gene expression in a GATA3 dependent manner. Here, we analyzed if this mechanism of flow-regulation of gene expression exists in vivo in the absence of inflammation. Results To experimentally mimic a shock-like situation, we developed a murine model of clonidine-induced hypotension by targeting a reduced mean arterial pressure (MAP) of approximately 50% over 4 h. We found that hypotension-induced reduction of flow in the absence of confounding disease factors (i.e., inflammation, injury, among others) is sufficient to suppress GATA3 and Tie2 transcription. Conditional endothelial-specific GATA3 knockdown (B6-Gata3tm1-Jfz VE-Cadherin(PAC)-cerERT2) led to baseline Tie2 suppression inducing spontaneous vascular leak. On the contrary, the transient overexpression of GATA3 in the pulmonary endothelium (jet-PEI plasmid delivery platform) was sufficient to increase Tie2 at baseline and completely block its hypotension-induced acute drop. On the functional level, the Tie2 protection by GATA3 overexpression abrogated the development of pulmonary capillary leakage. Conclusions The data suggest that the GATA3–Tie2 signaling pathway might play a pivotal role in controlling vascular barrier function and that it is affected in diverse critical illnesses with shock as a consequence of a flow-regulated gene response. Targeting this novel mechanism might offer therapeutic opportunities to treat vascular leakage of diverse etiologies.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 202
Author(s):  
Anna Egorova ◽  
Sofia Shtykalova ◽  
Alexander Selutin ◽  
Natalia Shved ◽  
Marianna Maretina ◽  
...  

Uterine leiomyoma (UL) is one of the most common benign tumors in women that often leads to many reproductive complications. Suicide genetherapy was suggested as a promising approach for UL treatment. In the present study, we describe iRGD ligand-conjugated cysteine-rich peptide carrier RGD1-R6 for targeted DNA delivery to αvβ3 integrin-expressing primary UL cells. The physico-chemical properties, cytotoxicity, transfection efficiency and specificity of DNA/RGD1-R6 polyplexes were investigated. TheHSV-1thymidine kinase encoding plasmid delivery to PANC-1pancreatic carcinoma cells and primary UL cells resulted in significant suicide gene therapy effects. Subsequent ganciclovir treatment decreased cells proliferative activity, induced of apoptosis and promoted cells death.The obtained results allow us to concludethatthe developed RGD1-R6 carrier can be considered a promising candidate for suicide gene therapy of uterine leiomyoma.


2010 ◽  
Vol 7 (2) ◽  
pp. 618-618
Author(s):  
Artphop Neamnark ◽  
Orawan Suwantong ◽  
Remant Bahadur K. C. ◽  
Charlie Y. M. Hsu ◽  
Pitt Supaphol ◽  
...  

2020 ◽  
Vol 3 (11) ◽  
pp. 7831-7839
Author(s):  
Xiao-He Ren ◽  
Xiao-Yan He ◽  
Bo-Ya Liu ◽  
Chang Xu ◽  
Si-Xue Cheng

Vaccine ◽  
2008 ◽  
Vol 26 (18) ◽  
pp. 2186-2190 ◽  
Author(s):  
A. Goubier ◽  
L. Fuhrmann ◽  
L. Forest ◽  
N. Cachet ◽  
M. Evrad-Blanchard ◽  
...  

Biomaterials ◽  
2007 ◽  
Vol 28 (31) ◽  
pp. 4693-4704 ◽  
Author(s):  
Başak Açan Clements ◽  
Vanessa Incani ◽  
Cezary Kucharski ◽  
Afsaneh Lavasanifar ◽  
Bruce Ritchie ◽  
...  

2019 ◽  
Vol 20 (11) ◽  
pp. 2776 ◽  
Author(s):  
Emilia Sokołowska ◽  
Agnieszka Urszula Błachnio-Zabielska

The gene delivery to skeletal muscles is a promising strategy for the treatment of both muscular disorders (by silencing or overexpression of specific gene) and systemic secretion of therapeutic proteins. The use of a physical method like electroporation with plate or needle electrodes facilitates long-lasting gene silencing in situ. It has been reported that electroporation enhances the expression of the naked DNA gene in the skeletal muscle up to 100 times and decreases the changeability of the intramuscular expression. Coelectransfer of reporter genes such as green fluorescent protein (GFP), luciferase or beta-galactosidase allows the observation of correctly performed silencing in the muscles. Appropriate selection of plasmid injection volume and concentration, as well as electrotransfer parameters, such as the voltage, the length and the number of electrical pulses do not cause long-term damage to myocytes. In this review, we summarized the electroporation methodology as well as the procedure of electrotransfer to the gastrocnemius, tibialis, soleus and foot muscles and compare their advantages and disadvantages.


2007 ◽  
Vol 35 (4) ◽  
pp. 829-832 ◽  
Author(s):  
R. Pipkorn ◽  
W. Waldeck ◽  
J.W. Jenne ◽  
B. Didinger ◽  
K. Braun

This paper presents the BioShuttle platform as a delivery vehicle for transfer of contrast agents and genetic material into target cells, which can be followed by activation of the BioShuttle inside the target cell. Here, we present a transporter system and summarize the findings on transporter use in vivo and in vitro. The results here are limited to examples where cargoes (drugs, genetically active materials or contrast agents) are covalently associated with the transporter module. A further example, in which the cargo is non-covalently attached to the BioShuttle, is also discussed. Finally, attempts have been made to solve some of the issues surrounding the efficiency of transfer of therapeutic or diagnostic agents and their later activity in the cell.


Sign in / Sign up

Export Citation Format

Share Document